Literature DB >> 25655164

Recovery, not progressive deterioration, should be the expectation in schizophrenia.

Robert B Zipursky1, Ofer Agid.   

Abstract

Entities:  

Year:  2015        PMID： 25655164      PMCID： PMC4329903          DOI： 10.1002/wps.20194

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  27 in total

1.  Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation.

Authors:  Anthony C Vernon; Sridhar Natesan; William R Crum; Jonathan D Cooper; Michel Modo; Steven C R Williams; Shitij Kapur
Journal:  Biol Psychiatry       Date:  2012-01-15       Impact factor: 13.382

2.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.

Authors:  Karl-Anton Dorph-Petersen; Joseph N Pierri; James M Perel; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

3.  Living in a Kraepelinian world: Kraepelin's impact on modern psychiatry.

Authors:  Assen Jablensky
Journal:  Hist Psychiatry       Date:  2007-09

4.  Brain volume changes in first-episode schizophrenia: a 1-year follow-up study.

Authors:  Wiepke Cahn; Hilleke E Hulshoff Pol; Elleke B T E Lems; Neeltje E M van Haren; Hugo G Schnack; Jeroen A van der Linden; Patricia F Schothorst; Herman van Engeland; René S Kahn
Journal:  Arch Gen Psychiatry       Date:  2002-11

Review 5.  Why are the outcomes in patients with schizophrenia so poor?

Authors:  Robert B Zipursky
Journal:  J Clin Psychiatry       Date:  2014       Impact factor: 4.384

Review 6.  Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective.

Authors:  J A Lieberman
Journal:  Biol Psychiatry       Date:  1999-09-15       Impact factor: 13.382

Review 7.  Longitudinal studies of cognition in schizophrenia: meta-analysis.

Authors:  Andrei Szöke; Anca Trandafir; Marie-Estelle Dupont; Alexandre Méary; Franck Schürhoff; Marion Leboyer
Journal:  Br J Psychiatry       Date:  2008-04       Impact factor: 9.319

8.  Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.

Authors:  Beng-Choon Ho; Nancy C Andreasen; Peg Nopoulos; Stephan Arndt; Vincent Magnotta; Michael Flaum
Journal:  Arch Gen Psychiatry       Date:  2003-06

9.  Early use of clozapine for poorly responding first-episode psychosis.

Authors:  Ofer Agid; Gary Remington; Shitij Kapur; Tamara Arenovich; Robert B Zipursky
Journal:  J Clin Psychopharmacol       Date:  2007-08       Impact factor: 3.153

10.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989
View more
  6 in total

1.  Implementing shared decision making in routine mental health care.

Authors:  Mike Slade
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

2.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

3.  Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits.

Authors:  Julia Vakhrusheva; Brielle Marino; T Scott Stroup; David Kimhy
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-04

Review 4.  Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature.

Authors:  Giulia M Giordano; Francesco Brando; Pasquale Pezzella; Maria De Angelis; Armida Mucci; Silvana Galderisi
Journal:  Front Psychiatry       Date:  2022-08-30       Impact factor: 5.435

Review 5.  Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia.

Authors:  Qiongqiong Wu; Xiaoyi Wang; Ying Wang; Yu-Jun Long; Jing-Ping Zhao; Ren-Rong Wu
Journal:  Neurosci Bull       Date:  2021-07-05       Impact factor: 5.203

6.  Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile.

Authors:  Renato de Filippis; Raffaele Gaetano; Georgios Schoretsanitis; Giuseppe Verde; Cesare Anthony Oliveti; John M Kane; Cristina Segura-Garcia; Pasquale De Fazio
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-01       Impact factor: 2.570
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.